Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674529 · ClinicalTrials.gov registry record · Phase 2
Study of Neural Responses Induced by Antidepressant Effects
A Phase 2 study, sponsored by Marta Peciña, MD PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02674529 is a Phase 2 study that has completed, run by Marta Peciña, MD PhD. The registered enrollment target is 60 participants.
The verdict
NCT02674529, a Phase 2 study, has completed, sponsored by Marta Peciña, MD PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
Interventions
- DRUG Placebo
- DRUG Escitalopram
- BEHAVIORAL Real-time Neurofeedback fMRI task pre- and post-RCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-09 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02674529
The ClinicalTrials.gov registry entry for NCT02674529 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marta Peciña, MD PhD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02674529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02674529 about?
NCT02674529 is a clinical study titled "Study of Neural Responses Induced by Antidepressant Effects". The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
What is the current status of trial NCT02674529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-09. Estimated completion is 2021-05.
What interventions are being tested in trial NCT02674529?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), Real-time Neurofeedback fMRI task pre- and post-RCT (BEHAVIORAL).
Who is sponsoring clinical trial NCT02674529?
This trial is sponsored by Marta Peciña, MD PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.